Mesothelioma Doctors

Dr. Robert C. Doebele is an associate professor in the division of medical oncology at the University of Colorado School of Medicine. He joined the University of Colorado in 2008 as a member of the thoracic malignancies program. In his tenure at the university, he co-founded and co-directs the University of Colorado Molecular Tumor Board, and acts as the Scientific Lead for ORIEN at the University of Colorado and a co-PI of the University of Colorado Lung Cancer SPORE. Dr. Doebele is also a senior editor at the American Association's Cancer Research (AACR) journal, Clinical Cancer Research. Prior to assuming these current roles, Dr. Doebele served as an instructor at the University of Chicago.

Dr. Doebele leads a translational research laboratory, which studies oncogenic gene fusions relative to lung cancer and employs cellular, genetic, molecular and translational approaches to identify the mechanisms of resistance in targeted lung cancer therapy. The research in his laboratory is aimed at identifying and analyzing oncogenes in lung cancer with the goals of advancing personalized medicine (targeted lung cancer therapies) and improving clinical outcomes for patients with various types of thoracic malignancies.

Main Specialty: Oncology

Other Interests & Specialties: General oncology, hematologic oncology and thoracic cancer.

Certifications, Awards & Accolades: American Board of Internal Medicine Certification in Medical Oncology, Boettcher Foundation Webb-Waring Biomedical Research Award

Education & Experience:

• Residency for Internal Medicine at University of Chicago
• Fellowship for Hematology/Oncology at University of Chicago
• Medical Degree from Perelman School of Medicine at the University of Pennsylvania

Publications:
Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Cancer Chemotherapy and Pharmacology. February 2013;71(2):307-19. doi: 10.1007/s00280-012-2008-6

Molecularly targeted therapies in non-small-cell lung cancer annual update 2014. Journal of Thoracic Oncology. January 2015;10(1 Suppl 1):S1-63. doi: 10.1097/JTO.0000000000000405

TRKing down an old oncogene in a new era of targeted therapy. Cancer Discovery. January 2015;5(1):25-34. doi: 10.1158/2159-8290.CD-14-0765

Phase 2, randomized, open-label study of ramucirumab in combination with first-line pemetrexed and platinum chemotherapy in patients with nonsquamous, advanced/metastatic non-small cell lung cancer. Cancer. March 2015;121(6):883-92. doi: 10.1002/cncr.29132

Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. Journal of Clinical Oncology. December 2014;32(34):3824-30. doi: 10.1200/JCO.2014.56.7412

Crizotinib in ROS1-rearranged non-small-cell lung cancer. The New England Journal of Medicine. November 2014;71:1963-1971.

The minority report: targeting the rare oncogenes in NSCLC. Current Treatment Options in Oncology. December 2014;15(4):644-57. doi: 10.1007/s11864-014-0310-8

A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non-small-cell lung cancer. Journal of Thoracic Oncology. October 2014;9(10):1532-9. doi: 10.1097/JTO.0000000000000273